Novartis AG
CD22 CHIMERIC ANTIGEN RECEPTOR (CAR) THERAPIES
Last updated:
Abstract:
The invention provides compositions and methods for treating cancer, e.g., hematological cancer, by administering a CD22 CAR-expressing cell described herein according to a dosage regimen described herein. Also disclosed are methods of making and compositions comprising the same.
Status:
Application
Type:
Utility
Filling date:
27 Sep 2019
Issue date:
17 Feb 2022